Kymera Therapeutics Inc. Common Stock vs NXP Semiconductors N.V. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while NXP Semiconductors N.V. Common Stock trades at $217.48 (market cap $57.07B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 6.4× Kymera Therapeutics Inc. Common Stock's market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and NXP Semiconductors N.V. Common Stock for 5 Days on average.
| KYMR | NXPI | |
|---|---|---|
Market Cap | $8.87B | $57.07B |
Volume | 779,107 | 3,033,835 |
Sector | Health | Technology |
52-Week High | $127.31 | $332.67 |
52-Week Low | $55.80 | $184.19 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $8.26B | $65.18B |
Dividend Yield | — | 1.79% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →